Compatible with standard qPCR and liquid handling instrumentation, the Plex Prime® SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.įounded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. This reagent is the third product in the Plex Prime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with Plex Prime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the Plex Prime®P681R Delta reagents. Plex Prime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda) 1, in addition to an RdRp gene target of SARS-CoV-2. “The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio.” “Rapid screening of positive samples with a PCR-based approach allows laboratories to easily monitor mutations as they circulate” said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs.
This reagent is the third product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime®P681R Delta reagents.
PlexPrime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)1, in addition to an RdRp gene target of SARS-CoV-2.
To view this piece of content from, please give your consent at the top of this page.
0 kommentar(er)
